Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Purpura, Schoenlein-Henoch D011695 5 associated lipids
Sclerosis D012598 5 associated lipids
Pulmonary Embolism D011655 5 associated lipids
Ductus Arteriosus, Patent D004374 5 associated lipids
beta-Thalassemia D017086 5 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Placenta Diseases D010922 5 associated lipids
Intracranial Embolism and Thrombosis D002542 5 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Facial Pain D005157 5 associated lipids
Bartter Syndrome D001477 5 associated lipids
Abortion, Habitual D000026 5 associated lipids
Mastocytosis D008415 5 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Coronary Stenosis D023921 6 associated lipids
Sneezing D012912 6 associated lipids
Thromboembolism D013923 6 associated lipids
Bronchitis D001991 6 associated lipids
Intermittent Claudication D007383 6 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Tanaka H et al. Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. 1999 Allergy pmid:10380781
Elissalde MH and Beier RC Stimulation and release of prostaglandins and thromboxane from macrophages by cotton dust associated lipopolysaccharides. 1990 Am Ind Hyg Assoc J pmid:2270833
Andersson T et al. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. 2012 Am J Cardiovasc Drugs pmid:22631032
Leese PT et al. Valdecoxib does not impair platelet function. 2002 Am J Emerg Med pmid:12098171
Jung TT and Juhn SK Prostaglandins in human cholesteatoma and granulation tissue. 1988 Am J Otol pmid:3177602
Mehta P et al. Plasma concentrations of thromboxane and prostacyclin metabolites in patients with bone tumors. 1985 Am J Pediatr Hematol Oncol pmid:2994511
Natarajan G et al. Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. 2008 Am J Perinatol pmid:18726836
Brown HL et al. Plasma and amniotic fluid prostacyclin and thromboxane in mild pregnancy-induced hypertension. 1987 Am J Perinatol pmid:3566883
Satterfield S et al. Biochemical markers of compliance in the Physicians' Health Study. 1990 Sep-Oct Am J Prev Med pmid:2268456
Ingster LM and Feinleib M Salicylate intake and cardiovascular disease: Ingster and Feinleib respond to Hu and Willett. 1998 Am J Public Health pmid:9702172
Cambria RA et al. Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia. 1991 Am Surg pmid:1847027
Smith EF and Lefer AM Stabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion:efficacy of the nonsteroidal anti-inflammatory agent, naproxen. 1981 Am. Heart J. pmid:7211667
Buerke M et al. Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. 1995 Am. Heart J. pmid:7661062
Cotter G et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? 2004 Am. Heart J. pmid:14760328
O'Connor KM et al. The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models. 1989 Am. Heart J. pmid:2929400
Neri Serneri GG et al. Abnormal cardiocoronary thromboxane A2 production in patients with unstable angina. 1985 Am. Heart J. pmid:3984828
Roy L et al. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease. 1985 Am. Heart J. pmid:3158183
Yamada Y et al. Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator. 1991 Am. Heart J. pmid:1903579
FitzGerald GA et al. Cigarette smoking and hemostatic function. 1988 Am. Heart J. pmid:3276116
Jouve R et al. Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy. 1984 Am. Heart J. pmid:6581715